Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
What were your top takeaways in SLE from ACR Convergence 2025?
Related Questions
Would you start hydroxychloroquine (or another DMARD) in a mid-20s female patient with positive ANA, SSA, SSB, and dsDNA, whose only clinical manifestation is intermittent parotid gland swelling?
Where do you introduce SGLT2 and GLP1 medications in the sequence of treatments for patients with lupus nephritis?
How would you approach a patient with SLE and catastrophic antiphospholipid antibody system that has not responded to heparin, steroids, and PLEX?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
How do you envision incorporating CAR-T therapy into your clinical practice?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
